HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by FRASER, I S Articles by MARKHAM, R. Search for Related Content PubMed PubMed Citation Articles by FRASER, I S Articles by MARKHAM, R.

Efficacy of Mefenamic Acid in Patients with a Complaint of Menorrhagia

From the Department of Obstetrics and Gynecology, University of Sydney, New South Wales, Australia

Abstract

Sixty-nine patients with a convincing history of menorrhagia completed a 4-cycle double-blind randomized placebo- controlled crossover trial of mefenamic acid taken during menstruation. Only 30 of these patients demonstrated objective menorrhagia with a measured menstrual loss greater than 80 ml during the placebo cycles, but the remainder reported passing clots and/or using 2 pads at a time. Fourteen of these women (20%) had a loss of less than 35 ml while taking placebos. This raises serious questions about the establishment of menorrhagia based on history alone. Overall, there was a mean reduction of 28.1% in menstrual blood loss between placebo and mefenamic acid cycles ( P<.001). The greatest reduction recorded was 80%, and most of the large percentage reductions were seen in patients with high loss during placebo cycles. Significant reductions in blood loss (P<.001) were seen in patients with ovulatory dysfunctional uterine bleeding and menorrhagia that developed after tubal interruption. There was also an indication based on small sample sizes that mefenamic acid reduced blood loss in women with anovulatory dysfunctional uterine bleeding, fibroids, intrauterine devices, and von Willebrand disease. No reduction was seen during the mefenamic acid cycle in the group with a loss of less than 35 ml during the placebo cycle. There was a significant shortening of duration of bleeding (P<.003). Fifteen patients (21.7%) experienced no objective reduction in blood loss.

This article has been cited by other articles:

				J.H.E. Promislow, D.D. Baird, A.J. Wilcox, and C.R. Weinberg Bleeding following pregnancy loss before 6 weeks' gestation Hum. Reprod., March 1, 2007; 22(3): 853 - 857. [Abstract] [Full Text] [PDF]

				I. S. Fraser, P. Warner, and P. A. Marantos Estimating Menstrual Blood Loss in Women With Normal and Excessive Menstrual Fluid Volume Obstet. Gynecol., November 1, 2001; 98(5): 806 - 814. [Abstract] [Full Text] [PDF]

				R J Lilford Hysterectomy: will it pay the bills in 2007? BMJ, January 18, 1997; 314(7075): 160 - 160. [Full Text]

				J. Bonnar and B. L Sheppard Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid BMJ, September 7, 1996; 313(7057): 579 - 582. [Abstract] [Full Text]